Thermo Fisher Scientific has announced the launch of Brilliance MRSA 2 Agar for rapid and reliable MRSA screening in 18hr.
This newly improved chromogenic medium saves time for infection-control teams by allowing rapid and reliable screening for methicillin-resistant Staphylococcus aureus (MRSA).
With accurate, easy-to-read results in 18 hours, Brilliance MRSA 2 Agar enables prompt initiation of appropriate infection-control measures to help minimise opportunities for further transmission of MRSA.
The enhanced formulation of Brilliance MRSA 2 Agar ensures even easier interpretation of results.
New inhibitory components in the medium further reduce the growth of non-target organisms, while a novel pink counter stain ensures that any organisms that do grow are easily distinguished from the distinctive blue MRSA colonies.
Brilliance MRSA 2 Agar is suitable for inoculation direct from screening swabs, or it can be used to plate out an isolate or suspension.
In trials, Brilliance MRSA 2 Agar demonstrated improved performance compared to the previous Brilliance MRSA formulation and alternative commercially available chromogenic MRSA media.
In a low-prevalence setting, it detected more MRSA positive samples than any other medium without a single false-positive result, achieving a positive predictive value of 100 per cent and a negative predictive value of 99.7 per cent.
